Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules

Abstract

We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly linking specific grant expenditures to private-sector innovations. Second, we take advantage of idiosyncratic rigidities in the rules governing NIH peer review to generate exogenous variation in funding across research areas. Our results show that NIH funding spurs the development of private-sector patents: a $10 million boost in NIH funding leads to a net increase of 2.3 patents. Though valuing patents is difficult, we report a range of estimates for the private value of these patents using different approaches.

Endogenous productivity of demand‐induced R&D: evidence from pharmaceuticals

“…At the NIH in particular, there is evidence that private lobbying efforts—presumably motivated by demand—can influence the direction of public funds (Hegde and Sampat, ). Also notably, recent empirical evidence based on exogenous “windfalls” of funding at the NIH identifies significant positive downstream effects of NIH‐funded research on private patenting rates—even when focusing only on the patents of drug candidates (Azoulay et al., ). Although Azoulay et al.…”

"Brain drain, brain gain... brain sustain?" Challenges in building portuguese human research capacity

“…Public investment in R&D positively influences the growth of the country's GDP (Coccia, 2008), as well as private spending on R&D (Azoulay et al, 2015;Lööf and Heshmati, 2005); such investment benefits research development at small and medium enterprises (Gonzalez and Pazó, 2008), compensates for market failures (Bozeman and Sarewitz, 2005) and increases scientific production (Wang and Shapira, 2015). Following this rationale, if Portugal wants to secure economic growth and position itself as one of European's most innovative countries, it needs to ensure financial sustainability for its well-developed research base and take advantage of the R&D potential in the country to excel in science and technology.…”

Multi-Omics Research Trends in Sepsis: A Bibliometric, Comparative Analysis Between the United States, the European Union 28 Member States, and China

“…With the new administration in the United States intending to downsize the 2018 National Institutes of Health (NIH) budget by 18.3%, or *$5.8 billion, optimizing investments in research has become critical. Moreover, given that a $10 million increase in public (NIH) funding results in a net increase of 2.3 patents in the biopharmaceutical sector (Azoulay et al, 2015), this intended downsizing noted above may have wide-ranging implications for the research and innovation capacity of the United States in the knowledge-based biotechnology innovation (Katz and Wright, 2017).…”